Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience

Core Insights - Jupiter Neurosciences, Inc. has launched Nugevia MND, a supplement aimed at enhancing cognitive function and supporting brain health, tapping into the $8 trillion longevity and wellness markets [1][4] - Nugevia MND combines JOTROL, a proprietary resveratrol-based platform, with NovaSOL Curcumin to target neuroprotective pathways and improve cognitive resilience [2][4] - The product is positioned to generate high-margin revenue by appealing to aging populations concerned about cognitive decline, while also complementing Jupiter's pharmaceutical pipeline [4][8] Product Details - Nugevia MND is designed to improve memory, clarity, executive function, and support mitochondrial function in brain cells, while reducing neuroinflammation and oxidative stress [7][8] - The supplement will be available through direct-to-consumer e-commerce platforms starting Fall 2025, with a recommended daily regimen of two capsules [4] Strategic Importance - The launch of Nugevia MND represents a strategic move for Jupiter to leverage its expertise in central nervous system (CNS) therapeutics within the consumer health market [3][4] - Insights gained from consumer use of MND and biomarker data from ongoing clinical trials will inform future cognitive health programs [3][4] Scientific Foundation - JOTROL has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, addressing previous issues of poor absorption and gastrointestinal side effects [9][10] - The product line aims to bring clinical-grade science into the wellness space, supporting mental clarity and cellular energy [11]